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Effects of Chronic Atrial Fibrillation on Active and Passive
Force Generation in Human Atrial Myofibrils
Alexandra Belus, Nicoletta Piroddi, Cecilia Ferrantini, Chiara Tesi, Olivier Cazorla, Luana Toniolo,
Maurice Drost, Giulia Mearini, Lucie Carrier, Alessandra Rossi, Alessandro Mugelli, Elisabetta Cerbai,
Jolanda van der Velden, Corrado Poggesi
Rationale: Chronic atrial fibrillation (cAF) is associated with atrial contractile dysfunction. Sarcomere remodeling
may contribute to this contractile disorder.
Objective: Here, we use single atrial myofibrils and fast solution switching techniques to directly investigate the
impact of cAF on myofilament mechanical function eliminating changes induced by the arrhythmia in atrial
myocytes membranes and extracellular components. Remodeling of sarcomere proteins potentially related to the
observed mechanical changes is also investigated.
Methods and Results: Myofibrils were isolated from atrial samples of 15 patients in sinus rhythm and 16 patients
with cAF. Active tension changes following fast increase and decrease in [Ca2] and the sarcomere length–passive
tension relation were determined in the 2 groups of myofibrils. Compared to sinus rhythm myofibrils, cAF
myofibrils showed (1) a reduction in maximum tension and in the rates of tension activation and relaxation; (2)
an increase in myofilament Ca2 sensitivity; (3) a reduction in myofibril passive tension. The slow -myosin heavy
chain isoform and the more compliant titin isoform N2BA were up regulated in cAF myofibrils. Phosphorylation of
multiple myofilament proteins was increased in cAF as compared to sinus rhythm atrial myocardium.
Conclusions: Alterations in active and passive tension generation at the sarcomere level, explained by translational
and post-translational changes of multiple myofilament proteins, are part of the contractile dysfunction of human
cAF and may contribute to the self-perpetuation of the arrhythmia and the development of atrial dilatation. (Circ
Res. 2010;107:144-152.)
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Chronic atrial fibrillation (cAF) is characterized by elec-tric, structural, and contractile remodeling that leads to
pronounced atrial contractile dysfunction and self-
perpetuation of the arrhythmia (reviewed elsewhere1). The
persistence of atrial contractile disorder after cardioversion to
sinus rhythm (SR) in patients with cAF has long been
reported2 and may have dramatic consequences as it favors
thromboembolic events.3 In spite of its clinical significance,
the exact mechanism of cAF-induced contractile dysfunction
is poorly understood.
Most investigations into the contractile dysfunction of cAF
remodeled atria have concentrated on structural alterations4,5
or disorders of excitation–contraction coupling.6,7 Recent
investigations high-light the role of sarcomere protein mod-
ifications in human cAF-associated contractile dysfunc-
tion.8–11 However, the functional impact of myofilament
protein changes in cAF is weakly documented because it is
difficult to obtain consistent measurements of functionally
relevant parameters on human cardiac preparations.
Studies on single myofibrils can significantly document
changes in the mechanical performance of human cardiac
sarcomeres because these preparations can be obtained in
large amounts from very small cardiac samples.12,13 Single
myofibrils are the smallest units of the contractile apparatus
that retain the organized myofilament lattice and its entire
ensemble of associated proteins. Mechanical measurements
of myofibril force combined with rapid perfusion switching
techniques have been developed recently to investigate fast
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kinetic events related to cross-bridge action and regulation in
human cardiac myofibrils.12–14
In this study, sarcomere mechanisms underlying passive and
active tension generation and relaxation of atrial myocardium
are dissected and compared in myofibrils from surgical samples
of cAF and control (SR) patients. In the same samples, we also
determined the myosin heavy chain (MHC) and titin isoform
expression and the phosphorylation level of several myofilament
proteins. The results show that myofilament proteins play a
direct role in the altered atrial mechanics associated with cAF
suggesting that sarcomere remodeling also contribute to the
progressive nature of the arrhythmia.
Methods
Patients
The investigation conforms with the principles outlined in the Declara-
tion of Helsinki and is approved by the local Ethics Committee (no.
2006/0023797). Samples of atrial appendages were obtained following
informed consent from 15 SR patients (672 years; 7;) and 16 cAF
patients (662 years; 9;) undergoing open heart surgery. In the cAF
patients, established atrial fibrillation (AF) was documented for at least
8 months. No significant difference was present in ejection fraction and
left atrial diameter between cAF and SR patients. Details for each
patient group are given in Online Table I, available in the Online Data
Supplement at http://circres.ahajournals.org.
Mechanical Measurements in Myofibrils
Fresh surgical samples were collected in a cold sterile saline solution
for myofibril isolation according to previously described methods.12
Techniques for mechanical measurements in human cardiac myofi-
brils were as previously described.12–14 Briefly, myofibrils were
transferred to a temperature controlled chamber filled with relaxing
solution (pCa8, 15°C). The selected myofibril was horizontally
mounted (initial sarcomere length 2.2 to 2.3 m) between a
cantilever force probe and a glass needle mounted on the lever arm
of a length control motor. Myofibrils were activated and relaxed by
rapid solution switching between 2 continuous streams of solutions.
Ionic strength of the experimental solutions was 200 mmol/L and pH
7.0. All solutions contained a MgATP-regenerating system and a
cocktail of protease inhibitors.12,13 To avoid the effects on myofibril
force and force kinetics of variable levels of contaminant inorganic
phosphate (Pi) in the solutions, [Pi] was reduced to less than
5 mol/L using a Pi scavenging system.12,13
Sarcomeric Protein Analysis
Myosin heavy chain isoforms
Polyacrylamide gel electrophoresis was used to determine MHC iso-
form composition (MHC- and MHC-) after denaturation in sodium
dodecyl sulfate (SDS-PAGE) following a procedure described by
Talmadge and Roy.15 Gels were silver stained for isoform recognition or
stained with Coomassie Blue for quantitative analysis. Each band
(MHC- or MHC-) was expressed as percent of the total MHC.
Titin Isoforms
Analysis of titin content in SR and cAF samples was adapted from
Cazorla et al.16 Titin content was analyzed with SDS-PAGE (2.5% to
7% acrylamide gradient gels) and stained with 0.1% Coomassie
Blue. The integrated optical density of MHC and titin peaks (both
N2B and N2BA isoforms) were determined on wet gel images to
measure both the total amount of titin relative to MHC and the ratio
N2BA:N2B. For each sample a range of loadings was electropho-
resed on the same gel. The optical density of titin and MHC peaks
were determined and plotted against their loading volume. The linear
part of this relation was fitted with a line regression and the slope
determined. The slope ratio of titin:MHC was taken as relative
amount of titin in the samples and used to determine the N2BA:N2B
ratio. Western blotting was performed with the antibodies Z1/Z2
(kindly provided by Dr S. Labeit, University of Mannheim, Ger-
many) to label the N-terminal of titin.
ProQ Phosphostaining
Atrial tissue samples from 8 SR and 8 cAF patients were TCA
(trichloroacetic acid)-treated as described previously to fix phosphor-
ylation status of myofilament proteins.17 Phosphorylation status of
myofilament proteins separated on a gradient gel was determined
using Pro-Q Diamond phosphostaining.17 All protein signals were
within the linear range and were corrected for protein content
determined by SYPRO Ruby staining.
Western Immunoblotting
Gel electrophoresis and Western immunoblotting were performed as
described previously10,18 to analyze content and phosphorylation of
cardiac myosin binding protein (cMyBP)-C and cardiac troponin (cTn)I.
Results
Active Tension Generation and Relaxation
Thin bundles of myofibrils obtained from atrial samples of 7 SR
and 8 cAF patients were maximally calcium activated at pCa 4.5
and relaxed at pCa 8.0 by rapid solution change. Representative
force responses of SR and cAF myofibrils to full activation-
relaxation cycles at 15°C are shown in Figure 1A. Average data
for maximal isometric tension (P0) and kinetic parameters of
maximal tension generation (kACT, rate constant of tension
generation following Ca2 activation; and kTR, rate constant of
tension redevelopment following release–restretch applied to the
myofibril under steady-state conditions of force generation) for
both SR and cAF myofibrils are in the Table.
P0 in SR myofibrils was close to that previously reported for
control human atrial myofibrils.12 P0 was significantly depressed
(30%) in cAF compared to SR myofibrils. Both kTR and kACT
were markedly slower (50%) in cAF than in SR myofibrils
(Table). The difference is evident in Figure 1B (left) where
tension activation traces of SR and cAF myofibrils are normal-
ized to maximal tension and then superimposed.
Non-standard Abbreviations and Acronyms
AF atrial fibrillation
cAF chronic atrial fibrillation
cMyBP-C cardiac myosin binding protein-C
cTn cardiac troponin
kACT rate constant of tension generation following rapid Ca
2
activation
kTR rate constant of tension generation following rapid mechani-
cal perturbation
kREL rate constants of the “slow” and “fast” phases of tension
decline following rapid Ca2 removal
MHC myosin heavy chain
nH Hill coefficient, slope of the pCa–tension relationship
P0 maximal Ca
2-activated tension
pCa log[Ca2]
pCa50 pCa at which active tension is 50% of P0
PK protein kinase
SR sinus rhythm
ssTnI slow skeletal troponin I
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As shown in Figure 1A, for both SR and cAF myofibrils,
active tension fully relaxed on step reduction of [Ca2] below
the contraction threshold (pCa 8.0). The time course of full
tension relaxation is shown in Figure 1B (right) where the
normalized relaxation transients are superimposed on a faster
time scale. In agreement with previous observations on
skeletal and cardiac myofibrils,19 relaxation of both SR and
cAF myofibrils is biphasic starting with a slow linear force
decay (rate constant, slow kREL) followed by a fast exponen-
tial relaxation phase (rate constant, fast kREL). It has been
shown that the slow force decay lasts as long as the
sarcomeres remain isometric, whereas the fast exponential
phase follows the “give” of one or more sarcomeres and is
dominated by intersarcomere dynamics.19 Average values for
the rates of both relaxation phases (Table) indicate that
relaxation kinetics were slower or tended to be slower in cAF
than in SR myofibrils. Fast kREL was reduced (by 35%
P0.05) and slow kREL tended to decrease (by 25% P0.1)
in cAF versus SR myofibrils.
MHC Isoform Expression
Slower force kinetics at maximal activation in the cAF myofi-
brils are consistent with previously described8,9,20 cAF induced
changes in the motor protein. Of the 2 MHC isoforms expressed
in human cardiac muscle MHC- is associated with higher
actomyosin ATPase activity and faster cross-bridge kinetics than
MHC-. Both SR and cAF myofibrils coexpressed MHC- and
MHC- isoforms (Figure 2A). As expected from previous
characterization of human atrial tissue21 MHC- represented the
largest fraction (50%) of the total amount of MHC. The
Figure 1. Force activation and relax-
ation of SR and cAF myofibrils. A,
Representative examples of maximum
tension activation and full relaxation in
response to sudden pCa changes by
fast solution switching in SR (left) and
cAF (right) myofibrils. Lower traces
show fast release–restretch protocol for
kTR registration. B, Time courses of ten-
sion activation (left, kACT) and relaxation
(right, slow and fast kREL) of SR and cAF
myofibrils superimposed after normaliza-
tion to maximal tension (same traces as
in A on faster time base).
Table. Mean Data for Passive Tension and Active Tension
Generation and Relaxation in Myofibrils from Seven SR and
Eight cAF Patient Samples
SR cAF
P Student
t Test
Resting tension, mN  mm2 7.980.59 (52) 3.260.38 (61) P0.01
Active tension generation
P0, mN  mm
2 1257 (52) 907 (61) P0.01
kACT, sec
1 3.730.18 (54) 2.000.10 (72) P0.01
kTR, sec
1 3.550.10 (46) 1.900.10 (64) P0.01
Active tension relaxation
Slow phase duration, ms 1266 (47) 1398 (61) NS
Slow kREL, sec
1 0.520.04 (47) 0.400.04 (61) P0.10
Fast kREL, sec
1 161 (47) 101 (62) P0.05
Resting sarcomere length, 2.250.01. Data are meansSE (no. of myofibrils).
Figure 2. MHC isoform expression in SR and cAF myofibrils.
A, Representative SDS-PAGE of the MHC isoform region of SR
and cAF samples. B, Relative distribution of the MHC isoforms
in SR and cAF atrial myofibrils (meansSE, n8). C, Total MHC
content expressed relatively to actin.
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MHC- fraction was larger in SR samples (70%) compared to
cAF (59%) (Figure 2B, n8 for both groups, P0.05). Total
MHC, measured as MHC/actin ratio for each atrial sample, was
the same in SR and cAF myofibrils (Figure 2C). The lower
content in MHC- in cAF myofibrils confirms the previously
reported shift of MHC isoforms from MHC- to MHC- for
cAF human atrial myocardium.8,9,20
Ca2 Sensitivity of Active Tension
Ca2 sensitivity of tension was investigated by activating
myofibrils with various pCa solutions then assembling the
pCa–tension relationship. Each preparation was exposed to up to
4 different pCa solutions. pCa 4.5 determined maximum Ca-ac-
tivated tension and pCa 8 fully relaxed the preparation between
each activation. Values of force at any given pCa were normal-
ized to maximal force at pCa 4.5. pCa–tension points were fit to
a Hill equation and the pCa at which tension was half maximum
(pCa50) and the Hill coefficient (nH; slope of the pCa–tension
relationship) were determined for each group.
pCa–tension relationships for SR and cAF myofibrils are
given in Figure 3, with representative experimental traces at
indicated pCa values. The pCa–tension relationship for cAF
was clearly shifted to the left compared to that of SR
myofibrils. Average pCa50 was 5.830.10 in cAF, which was
significantly different (P0.05) from pCa50 of SR myofibrils
(5.610.03). The average nH was 2.160.30 in SR and
1.440.43 in cAF myofibrils (P0.05).
Sarcomeric Protein Phosphorylation
To investigate if the higher Ca2 sensitivity of force in cAF
can be ascribed to differences in myofilament protein phos-
phorylation between SR and cAF sarcomeres, myofibril
proteins were separated on 1D gradient gels and stained with
SYPRO Ruby and Pro-Q Diamond (Figure 4). On average, no
significant difference was found in cTnI phosphorylation
between SR and cAF, whereas phosphorylation of cMyBP-C,
desmin, cTnT, and atrial light chain-2 was significantly
higher in cAF compared to SR samples.
The increase in cMyBP-C phosphorylation found in human
cAF using the Pro-Q Diamond phosphostaining (Figure 4B)
is in sharp contrast with previously reported decrease in
cMyBP-C phosphorylation measured with specific phospho-
cMyBP-C antibody10 in human cAF atria. To determine
whether the opposite result was attributable to the different
measurement methods we analyzed the content and phos-
phorylation of cMyBP-C and cTnI of our cAF and SR
samples using Western immunoblotting. The analysis re-
vealed no changes in cMyBP-C (Figure 5A) and cTnI (Figure
5B) protein content in cAF samples compared to SR. In
accordance with ProQ analysis of protein phosphorylation,
the specific antibodies directed against phosphorylated pro-
tein kinase (PK)A sites in cMyBP-C (Ser282) and cTnI
(Ser23/24) showed higher cMyBP-C phosphorylation in cAF
compared to SR (P0.08, Figure 5A) and confirmed no
difference in cTnI phosphorylation at Ser23/24 (Figure 5B).
The previously reported decrease in cMyBP-C phosphor-
ylation in cAF10 may reflect atrial dilatation rather than being
a component of cAF because, at variance with the present
study (see Online Table I), in the previous study10 the atrial
size of SR patients was much less than that of cAF patients
(see the table in the article by El-Armouche et al10). Consis-
tent with this explanation, a recent study in goat models of
atrial dilatation and atrial fibrillation22 has reported that
reduction in PKA phosphorylation of cMyBP-C is a distinc-
tive feature of atrial dilatation.
Passive Tension
Passive tension at optimum overlap was lower in cAF
compared to SR myofibrils (Table), suggesting that passive
stiffness differs in the 2 myofibril types. To better investigate
passive properties, the force responses of relaxed SR and cAF
myofibrils to various ramp elongations were recorded and the
steady-state sarcomere length–resting tension relationship
determined in the 2 myofibril groups (Figure 6). Sarcomere
length and resting tension were measured 20 seconds after
each length change was completed, ie, when most of the
stress relaxation was over. Details of the length elongation
protocol applied to myofibrils are shown in the inset of Figure
6 together with tension traces for a representative SR myofi-
bril. The average sarcomere length–passive tension relation-
ships of SR and cAF myofibrils (Figure 6) are evidence that
passive stiffness is significantly reduced in cAF myofibrils.
Titin Isoform Expression
Mammalian cardiac muscle coexpresses 2 titin isoforms, a
short N2B and a long, more compliant, N2BA titin.16–23
Considering that titin is the only significant source of resting
Figure 3. pCa–tension relationships of SR and cAF myofi-
brils. Top, Representative traces from cAF and SR myofibrils at
indicated pCa values. Bottom, Mean pCa–tension relationships
for cAF (E) and SR myofibrils (f). Tension values are normalized
to those measured at pCa 4.5. Data points are meansSE of 6 to
12 myofibrils from 4 SR and 4 cAF patients. Data are fit to a modi-
fied Hill equation (continuous lines): PP0/(110
[nH{pCa-pCa50}]).
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tension in single myofibrils, we investigated whether the
lower passive stiffness found in cAF myofibrils correlates
with changes in titin isoform expression.
In Figure 7A, SDS-PAGE reveals that human atrium
coexpresses N2B and N2BA titin isoforms; this is confirmed
by Western blotting. Titin degradation product T2 was hardly
detectable and T3 undetectable in our human atrial samples
indicating a good titin preservation. As shown in Figure 7B,
SR atrial tissue (n6) expressed more N2BA (61%) than
N2B (39%) and cAF (n6 patients) expressed even more
N2BA than SR (78%, P0.01). The titin/MHC ratio was the
same in SR and cAF patients (Figure 7C). Therefore, the total
content of titin was not different in SR and cAF atrial tissue
but the mean expression of N2BA in cAF was increased at the
expense of N2B.
Discussion
Passive and active mechanics of human atrial myofibrils are
significantly altered in cAF indicating that myofilament
changes contribute to the atrial contractile dysfunction that
persists after cardioversion. The decrease in passive stiffness
in the cAF myofibrils can be entirely explained by the shift in
titin isoform expression. Besides contributing to the altered
mechanics of cAF atria, changes in sarcomere diastolic
properties likely participate in the progressive atrial dilatation
that often accompanies cAF. The contractile alterations found
in cAF myofibrils can be only partly explained by the shift in
the isoform expression of the cardiac motor protein. Altered
phosphorylation of multiple myofilament proteins are likely
related to most contractile alterations. Changes associated
with increased myofilament Ca2 sensitivity may play a role
in the self-perpetuation of cAF.
The observed mechanical changes seem to be a component
of cAF rather than atrial dilatation because the atrial size of
cAF patients, although relatively large, is not significantly
different from that of SR patients (see Online Table I).
Changes in Titin and Diastolic Stiffness
To our knowledge titin isoform expression has never been
studied in human atrial myocardium. We find that the
N2BA:N2B expression ratio in the atrial myocardium of SR
patients is 1.640.27, much higher than that reported for
ventricular myocardium of normal human hearts (0.56
0.06).24 Interestingly, in humans as in other big mammals,16
the expression of N2BA dominates in atrial myocardium. It is
an important finding that the N2BA isoform is significantly
upregulated at the expense of the N2B isoform in cAF
(N2BA:N2B 3.800.50). As expression shifts toward the
N2BA isoform, because of the different compliance of the 2
titin isoforms, passive myofibril stiffness is expected to
decrease. Consistent with this notion, passive stiffness of cAF
myofibrils is significantly reduced (on average 2.5-fold)
compared to SR myofibrils.
It has been reported that the length dependence of activa-
tion of cardiac muscle (that is the mechanism underlying the
Figure 4. Myofilament protein phos-
phorylation. A, Tissue samples (20
g/lane) were separated on a 4% to
15% gradient gel stained with SYPRO
and Pro-Q Diamond. ProQ Diamond–
stained signals (cMyBP-C; desmin;
cTnT; cTnI; and atrial light chain 2 [ALC-
2]) were divided by SYPRO-stained pro-
tein signals to correct for differences in
protein loading. PM indicates molecular
weight marker (PeppermintStick phos-
phoprotein marker in which ovalbumin
and -casein are phosphorylated). B,
Student’s t test analysis revealed signifi-
cantly higher phosphorylation of
cMyBP-C, desmin, cTnT, and atrial light
chain-2 in cAF (n8) compared to SR
(n8). Values are given relative to SR
group, which was set to 1. *P0.05, cAF
vs SR.
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Starling’s law of the heart) is titin-based and is reduced in
preparations that express high levels of N2BA titin.25 One can
speculate, therefore, that length dependence of activation is
reduced in cAF myofibrils because of the increase in N2BA
titin. A reduction in the length dependence of activation will
contribute to cAF induced atrial contractile dysfunction and
possibly to progressive dilation. Progressive atrial dilation in
cAF26 may contribute to self-perpetuation of the arrhyth-
mia.27 The mechanism behind cAF related increase in atrial
size is unclear but increase in N2BA expression and reduction
in myofibril resistance to elongation may contribute to it.
Alterations in Contractile Function
The major changes in contractile function of cAF compared
to SR myofibrils are (1) a marked reduction in the maximum
rate of tension generation, (2) a significant decrease in
maximum active tension, and (3) a significant increase in
myofilament Ca2 sensitivity.
In both SR and cAF myofibrils, kACT was the same as kTR.
This similarity suggests that kACT is not limited by the rate with
which thin filaments are switched on by Ca2; rather it predom-
inantly reflects the rate with which crossbridges enter their force
generating states. Both kACT and kTR were markedly reduced
(50%) in cAF compared to SR myofibrils indicating a slower
cross-bridge turnover rate. Consistent with the present results, a
significant reduction in kTR was previously reported in perme-
abilized human atrial myocytes from cAF patients.9 Relaxation
kinetics, determined by sudden Ca2 removal from myofibrils,
predominantly reflects the apparent rate with which attached
crossbridges leave force-generating states.19 Relaxation rates
were slower (25% to 35%) in the cAF myofibrils than in the SR
myofibrils implying that both cross-bridge attachment and de-
tachment rates contribute to the slower overall cross-bridge
turnover in cAF myofibrils.
Increase in the relative amount of the slow MHC- isoform
expressed in cAF versus SR myofibrils (41% versus 30%),
though smaller than in previous reports (63% versus 25%20;
41% versus 23%9), directly accounts for the reduction in
activation and relaxation kinetics of cAF compared to SR
myofibrils. The negative impact of the MHC isoform change
on the power output and velocity of atrial contraction may
contribute to atrial contractile dysfunction in cAF.
Maximal Ca2 activated tension was reduced by 30% in
cAF compared to SR myofibrils. Similar effect of cAF on
maximal active tension (33% reduction) was recently reported
for permeabilized human atrial myocytes,9 though in that study
the difference between cAF and SR maximal tension was not
significant. A 75% reduction in twitch tension has been reported
in intact atrial trabeculae from cAF patients compared to SR
patients.6 In that study, however, following positive inotropic
Figure 5. cMyBP-C and cTnI protein
content and phosphorylation at PKA
sites. Western blot analysis did not
reveal reduced content or degradation of
cMyBP-C (A) and cTnI (B). In accor-
dance with ProQ analysis of protein
phosphorylation, cMyBP-C phosphoryla-
tion at Ser282 was higher in cAF than in
SR (A), whereas phosphorylation at
Ser23/24 in cTnI did not differ between
SR and cAF. NF indicates nonfailing
ventricular donor sample included as
positive control (B). Values are given rel-
ative to SR, which was set to 100%.
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interventions (high extracellular [Ca2], postrest potentiation)
the difference in twitch tension decreased to 15% consistent
with the AF-induced reduction in myofibril density per unit
cross sectional area of the trabeculae (-14%). Those results
suggested that most of the atrial contractile dysfunction of cAF
is associated with impaired Ca2 handling whereas the loss of
atrial myofibrils plays a minor role. Here we directly determined
the maximal tension of isolated myofibrils and eliminate con-
tamination by either AF-induced excitation–contraction cou-
pling dysfunction or myofibrillar loss. Thus, in cAF myofibrils
reduction in maximal active tension must be attributable to
defects in the myofilament themselves.
The shift in MHC expression toward the slow  isoform in
the myofibrils of AF patients is an unlikely explanation for
reduction in maximal tension of cAF myofibrils; maximal
tension does not differ in human atrial and ventricular
myofibrils that express quite different patterns of MHC
isoforms.12 Though maximal active tension loss of cAF
myofibrils may come from multiple sources, present results
support a role for altered phosphorylation of myofilament
proteins (see below).
We found evidence that regulation of contraction at the
myofilament level is also altered in cAF. pCa50 of active tension
was significantly increased, whereas the Hill coefficient (nH)
was decreased in cAF myofibrils compared to SR myofibrils. No
significant change in Ca2 sensitivity of tension development
has been previously reported for permeabilized human cAF
preparations,8,9 though a significant increase in the Ca2 sensi-
tivity of ATP consumption under isometric conditions has been
found in the same cAF preparations.8 This latter observation
seems consistent with the present results, although a discrepancy
between the Ca2 sensitivity of force and isometric ATPase is
difficult to explain.
Several mechanisms, mostly leading to changes in regulatory
proteins associated with thin and thick filaments, can impact the
pCa–tension relationship of atrial myofibrils. cAF is accompa-
nied by re-expression of fetal genes in the atria.3,4 The predom-
inant TnI isoform expressed by the fetal human heart is the slow
skeletal (ssTnI) isoform28,29; this imparts higher Ca2 sensitivity
to cardiac sarcomere.30 Although re-expression of ssTnI has
been described in the early stages of AF in human atria and in a
goat model of the disease, ssTnI was undetectable in atrial
samples from patients with cAF.31 A relation has been found in
human atria between cAF and the activity of calpain-1,32 a
protease involved in degradation of contractile proteins,33 in-
cluding cTn.34 Degradation of cTn by calpain has been reported
to occur in both human cAF and a cell model for tachypacing-
induced remodeling.11 The predominant cTnI degradation prod-
uct (cTnI1 to 192) has been shown to significantly increase Ca2
sensitivity of human cardiac myofibrils.14 However, in the
present and previous studies9,31 no changes in troponin content
were observed and cTnI degradation products were undetectable
in atrial samples from cAF patients.
The most likely explanation for the increased Ca2 sensitivity
and reduced maximal force resides in the complex changes in
myofilament protein phosphorylation found in cAF versus SR
samples. As previously reported,9,10 phosphorylation of cTnI—the
primary sarcomere target of PKA—was the same in cAF and SR
atria. Our analysis revealed, instead, significantly higher phos-
phorylation of other myofilament proteins in cAF. CaMKII
(Ca2/calmodulin-dependent protein kinase II) is overexpressed
in human cAF35 and this may explain why cMyBP-C phosphor-
ylation is increased because Ser282 is both a PKA and CamKII
site. Increased phosphorylation of cMyBP-C in the absence of
Figure 6. Passive tension in SR and cAF myofibrils. Average
sarcomere length–passive tension relationships for SR (f, con-
tinuous line) and cAF (E, dashed line) myofibrils. Data are
meansSE of 9 to 15 myofibrils from 6 SR and 6 cAF patients.
In the inset, representative passive tension responses (lower
traces) to ramp elongations (upper traces) of SR myofibril in
relaxing conditions (pCa 8.0).
Figure 7. Titin isoform expression in SR and cAF atrial myo-
cardium. A, SDS-PAGE of SR and cAF myocardium. Rat car-
diac degraded control (CD) was coelectrophoresed for isoform
reference. Top right, Expanded titin region with evidence that
degradation product T2 is hardly detectable and T3 undetect-
able in the human atrial samples. Bottom right, Western blot
using the antibody Z1/Z2 for isoform band confirmation. B, Titin
isoform percent distribution in SR and cAF (meansSE, n6,
P0.01). C, Total titin content, expressed relatively to MHC in
SR and cAF atrial tissue (meansSE, n6, P0.9).
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increased PKA phosphorylation of cTnI may increase myofibril
Ca2 sensitivity,36 though the specific effect of cMyBP-C
phosphorylation on Ca2 sensitivity of tension is at present
unresolved.37 Increased atrial light chain-2 phosphorylation by
myosin light chain kinase or PKC has been associated with
increased myofilament Ca2 sensitivity,38,39 whereas increased
cTnT phosphorylation by PKC has been implicated in reduced
maximal force generating capacity.40 As conclusion, present
results suggest that the increased Ca2-responsiveness and the
lower maximal tension of cAF myofibrils cannot be explained
by contractile protein degradation or isoform shifts but result
from the complex interplay between changes in the phosphory-
lation status of multiple myofilament proteins.
The fact that phosphorylation of multiple myofilament
proteins is increased favors a role for altered phosphatase
rather than kinase activity, which would result in more
specific protein phosphorylation changes. A role for altered
phosphatase activity in cAF has been suggested in a previous
study10 and warrants further investigation of protein phospha-
tases and their cellular compartmentalization.
In intact cAF myocardium, increased myofilament Ca2
sensitivity may partly counteract the decrease in active force
generation and impaired excitation–contraction coupling but
may have detrimental effects on relaxation. Moreover, in-
crease in Ca2 sensitivity of cAF myofibrils may contribute
to electric remodeling and self-perpetuation of atrial arrhyth-
mia. Because Ca2 binding to the troponin complex repre-
sents the largest component of dynamic Ca2 buffering
during the cardiac cycle, intracellular Ca2 transients may
significantly change with altered myofilament Ca2 sensitiv-
ity.41,42 This, in turn, may lead to action potential remodeling
and altered intracellular Ca2 handling to create both an
arrhythmogenic substrate and a trigger in atrial myocardium.
In isolated mouse heart myofilament Ca2-sensitization by
drugs or troponin mutations associated with familial hyper-
trophic cardiomyopathy are reported to induce arrhythmias
by (1) shortening the effective refractory period and the
action potential duration, (2) slowing conduction velocity,
and (3) predisposing to early after-depolarizations and trig-
gered activity.43
Clinical Implications
This study provides new insights into the alterations of
myofilament function in cAF that may help us understand
persistent atrial contractile dysfunction, a major contributor to
atrial thrombogenesis. In cAF remodeled sarcomeres, we
identified altered titin isoform expression and increased
myofilament Ca2 sensitivity as contributors to progressive
and self-perpetuating arrhythmia. If mechanoelectric feed-
back between increased myofilament Ca2 sensitivity and
increased propensity for arrhythmias will be definitely estab-
lished, restoration of sarcomere Ca2 sensitivity (likely via
restoration of myofilament protein phosphorylation levels)
may become a novel therapeutic option for AF treatment.
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Novelty and Significance
What Is Known?
● Chronic atrial fibrillation (cAF) is associated with persistent atrial con-
tractile dysfunction, a major contributor to atrial thrombogenesis.
● Mechanisms responsible for impaired contractility are poorly defined
and available therapies do not address this dysfunction.
● Most studies focus on alterations in atrial myocyte Ca2 handling, but we
and others emphasize the role of myofilament protein remodeling.
What New Information Does This Article Contribute?
● We demonstrate that diastolic and systolic sarcomere mechanics and
myofilament Ca2 sensitivity are altered in atrial myofibrils from
cAF patients.
● These mechanical changes are explained by shifts in protein isoforms
and by increased phosphorylation of multiple myofilament proteins.
● Myofilament remodeling is part of atrial contractile dysfunction in
human cAF and probably contributes to the progressive and
self-perpetuating nature of the arrhythmia.
It is hypothesized that maladaptive remodeling of the myofila-
ments is responsible, at least in part, for human cAF-associated
atrial contractile dysfunction. To document the functional impact
of myofilament protein changes in human cAF we dissected the
sarcomere diastolic and systolic properties of single atrial
myofibrils from surgical samples of cAF and control patients.
cAF myofibrils show (1) a reduction in diastolic stiffness, (2) a
reduction in maximum active tension and in the rates of
contraction and relaxation, and (3) an increase in myofilament
Ca2 sensitivity. These mechanical changes are associated with
changes in myofilament proteins. In cAF remodeled sarcomeres
we identify altered titin and myosin isoform expression and
increased levels of phosphorylation of multiple proteins. The
latter finding suggests that altered phosphatase activity leads to
increased Ca2 sensitivity that, in turn, may contribute to the
self-perpetuation of the atrial arrhythmia. These results show
that translational and post-translational changes in myofilament
proteins play a direct role in the altered atrial mechanics
associated with cAF and contribute to the progression of the
arrhythmia. Restoration of sarcomere Ca2 sensitivity (likely via
restoration of myofilament protein phosphorylation levels) may
become a novel therapeutic option for AF treatment.
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ONLINE SUPPLEMENT MATERIAL 
 
DETAILED METHODS 
Patients 
The investigation conforms with the principles outlined in the Declaration of Helsinki and is 
approved by the local Ethics Committee (n. 2006/0023797). Samples of atrial appendages were obtained 
following informed consent from 15 SR patients and 16 cAF patients undergoing open heart surgery. In the 
cAF patients established AF was documented for at least 8 months. Samples from SR patients were used as 
controls. No significant difference was present in ejection fraction and left atrial size between cAF and SR 
patients. Details for each patient group are given in Online Table I. 
 
Myofibril preparation 
Fresh surgical samples were collected in a cold sterile saline solution for myofibril isolation. 
Myofibril suspensions were prepared according to previously described methods1-2. 
Mechanical measurements 
Techniques for mechanical measurements in myofibrils were as previously described1-3. Briefly, 
myofibrils were transferred to a temperature controlled chamber filled with relaxing solution (pCa8, 15°C). 
The selected myofibril was horizontally mounted between a cantilever force probe (compliance: 2–6 nm.nN-
1) and a glass needle mounted on the lever arm of a length control motor. Initial sarcomere length (SL) was 
adjusted to optimum myofilament overlap (2.2-2.3 µm). Average SL and width of mounted myofibrils were 
measured on video images acquired through a CCD camera (2000x; phase contrast optics). 
Isometric force was measured photoelectronically by recording the force probe deflection. 
Myofibrils were activated and relaxed by rapid solution switching between two continuous streams of 
solutions. Release-restretch protocols were applied to myofibrils in relaxing solution to measure passive 
tension or in activating solution at the contraction plateau (Fig 1) to measure the rate of tension 
redevelopment (kTR)4. 
Solutions 
Ionic strength of the experimental solutions was 200mM and pH 7.0. Measurements were made in 
the presence of a MgATP regenerating system (10 mM creatine phosphate, 200 units.ml-1 creatine kinase). 
To avoid the effects on myofibril maximal force and force kinetic of variable level of contaminant inorganic 
phosphate (Pi) in the solutions, [Pi] was reduced to less than 5µM using a Pi scavenging system1-3. All 
solutions contained a cocktail of protease inhibitors1-3. 
 
Sarcomeric protein analysis 
 
Myosin heavy chain isoforms 
Polyacrylamide gel electrophoresis was used to determine MHC isoform composition (MHCα and MHCβ) 
after denaturation in sodium dodecyl sulphate (SDS-PAGE).  
After mechanical measurements were completed the remaining myofibril suspensions were centrifuged and 
the pellets were re-suspended in 100µl of Laemmli buffer and boiled for 5 min at 80ºC. Appropriate 
quantities of the protein suspension were loaded onto gels (almost 1 µg of total protein). Cardiac MHC 
isoforms were separated on 8% Polyacrylamide slab gels after denaturation in SDS following a procedure 
described by Talmadge and Roy4. Slabs gel 18cm wide, 16cm high and 1mm thick were ran at 4°C for 40 h 
(2 h at 70V then at 170V for the time remaining). The gel thickness was increased (1mm instead of 0.75mm) 
in order to reduce the resistance; the lower voltage at a prolonged running time allowed us to achieve the 
resolution required for the separation of the two cardiac MHC isoforms. Gels were silver stained (Bio-Rad 
Silver stain plus) for isoform recognition or stained with Coomassie Blue for quantitative analysis. 
The Coomassie Blue gels were digitized with a scanner EPSON 1650 at a resolution of 1200 dpi. 
Each line was characterised by a Brightness-Area Product (BAP) with a constant threshold after black/white 
inversion using Adobe Photoshop. 
Each band (MHC-α or MHC-β) was expressed as percent of the total MHC. 
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Titin isoforms 
Analysis of titin content in SR and cAF samples was adapted from Cazorla et al.5. Human atrial 
tissue was pulverized in liquid nitrogen and solubilised for 3 min at 60°C in Laemmli buffer supplemented 
with 8M urea. Titin content in SR and cAF samples were analysed with SDS-PAGE (2.5-7% acrylamide 
gradient gels) and stained with 0.1% Coomassie Blue. 
Wet gel images were acquired with a Kodak Image Station 2000R and analysed using Kodak 1D 
image analysis software. The integrated optical density of MHC and titin peaks (both N2B and N2BA 
isoforms) were determined to measure both the total amount of titin relative to MHC and the ratio 
N2BA:N2B. For each sample a range of loadings was electrophoresed on the same gel. The optical density 
of titin and MHC peaks were determined and plotted against their loading volume. The linear part of this 
relation was fitted with a line regression and the slope determined. The slope ratio of titin:MHC were taken 
as relative amount of titin in the samples and used to determine the N2BA:N2B ratio. Western blotting was 
performed with the antibodies Z1/Z2 (kindly provided by Dr Labeit) to label the N-terminal of titin. 
 
ProQ Phosphostaining  
Atrial tissue samples from 8 SR and 8 cAF hearts were TCA (tri-chloro acetic acid)-treated as described 
previously to fix phosphorylation status of myofilament proteins6. Phosphorylation status of myofilament 
proteins was determined using Pro-Q Diamond phosphostaining (Molecular Probes)6. Samples were 
separated on a gradient gel (Criterion Tris-HCl 4-15% gel, BioRad) and proteins were stained for one hour 
with Pro-Q Diamond Phosphoprotein Stain. Fixation, washing and de-staining were performed according to 
the manufacturer’s guidelines. Staining was visualized using the LAS-3000 Image Reader (FUJI; 460 
nm/605 nm Ex/Em; 2 min illumination) and signals were analyzed with AIDA. All protein signals were 
within the linear range. Subsequently gels were stained overnight with SYPRO Ruby stain (Molecular 
Probes) and visualized with the LAS-3000 (460 nm/605 nm Ex/Em; 2 s illumination). Since illumination of 
Pro-Q Diamond-stained gels for 2 seconds did not reveal any signal, the signals obtained upon SYPRO Ruby 
staining are not tainted by Pro-Q signals. All protein phosphorylation signals were corrected for protein 
content determined by SYPRO staining. 
 
Western Immunoblotting 
Gel electrophoresis and Western immunoblotting was performed as described previously7-8  
to analyze content and phosphorylation of myosin binding protein C and troponin I. Shortly, for the 
analysis of cMyBP-C 15µg of proteins were loaded on a 10% acrylamide/bisacrylamide (29:1) gel 
and electro-transferred onto nitrocellulose membrane. Membranes were stained with polyclonal 
antibodies directed against cMyBP-C (MyBP-C motif 1:2500, pSer282-cMyBP-c 1:1000). After 
incubation with HRP-secondary antibody (Sigma), the signal was revealed with ECL Plus 
(Amersham) and acquired with the ChemiImagar TM 5500 (Alpha Innotech). For troponin analysis 
0.5 µg and 5 µg sample was loaded to analyse expression (antibody 8I7, 1:15.000, Spectral 
diagnostics) and phosphorylation (pSer23/24, 1:1000, Cell signaling), respectively.  Troponin values 
were normalized to actin stained on the same blots. 
 
 
 
Statistical analysis 
Data are presented as means ± SE. Differences between group means were compared by unpaired 
Student t test. P<0.05 was considered statistically significant. 
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ONLINE TABLE I: Patient data 
 
 
 cAF SR 
Total number of patients  16 15 
Gender, n of female 9 7 
Age, years 65.9±1.7 67.2±1.9 
Body mass index, kg/m2  27.1±0.7 26.8±1.2 
Reason for surgery: 
• CAD, n 
• MVD/AVD, n 
• CAD+ MVD/AVD, n 
 
 
6 
6 
4 
 
 
11* 
3 
1 
NYHA functional class at time of surgery:  
• I, n 
• II, n 
• III, n 
• IV, n 
 
 
7 
7 
2 
-- 
 
8 
6 
1 
-- 
LVEF, % 57.7±2.7 59.1±3.2 
Left atrial diameter (mm) 53.6±1.7 49.8±1.2 
 
CAD, coronary artery disease; MVD, Mitral valve disease requiring valve replacement; AVD, Aortic valve 
disease requiring valve replacement; LVEF, left ventricular ejection fraction. *P<0.05, nonpaired Student t 
test for continuous variables and Х2 test for categorical variables. 
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